5-乙基-2-甲基-苯酚 | 1687-65-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 5-乙基-2-甲基-苯酚
• 中文别名: 3-羟基-4-甲基苯乙酮
• 英文名称: 2-methyl,5-ethyl-phenol
• 英文别名: 2-methyl-5-ethylphenol；5-ethyl-2-methylphenol；5-ethyl-2-methyl-phenol；5-Aethyl-2-methyl-phenol；2-Hydroxy-1-methyl-4-aethyl-benzol；5-ethyl-o-cresol
• CAS: 1687-65-6
• 化学式: C₉H₁₂O
• 分子量: 136.194
• InChiKey: AYGDIAGADYTJRY-UHFFFAOYSA-N

物化性质

• 熔点：
  15°C
• 沸点：
  227.7°C
• 密度：
  0.9809 (estimate)
• 稳定性/保质期：
  存在于主流烟气中。

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2905199090

反应信息

• 作为反应物：
  描述：

  5-乙基-2-甲基-苯酚 在 palladium diacetate 、 sodium acetate 、 sodium hydride 、 三苯基膦 作用下， 以 四氢呋喃 、 N,N-二甲基乙酰胺 为溶剂， 反应 24.0h， 生成 1-ethyl-4-methyl-6H-benzo[b]naphtho[1,2-d]pyran-6-one
  参考文献：
  名称：

  Atropisomerization Barriers of Configurationally Unstable Biaryl Compounds, Useful Substrates for Atroposelective Conversions to Axially Chiral Biaryls

  摘要：

  Configurationally unstable biaryl lactones of type (M)-1 reversible arrow (P)-1 and ring-opened 2-acyl-2'-hydroxy biaryl compounds of type (M)-4 reversible arrow (P)-4 are versatile precursors for the atroposelective preparation of axially chiral biaryls. The activation barriers of their atropisomerization process, which constitutes a fundamental precondition for the dynamic kinetic resolution, were determined by dynamic NMR spectroscopy for rapid processes and by HPLC-monitored racemization of enantiomerically enriched material for smaller interconversion rates. For the lactones, the free activation energies Delta G(298)(double dagger) increase with the steric demand of the substituent R ortho to the biaryl axis in the series H < OMe (t(1/2) approximate to ms) < Me (t(1/2) approximate to s) < Et < i-Pr (t(1/2) approximate to min) < t-Bu (t(1/2) approximate to d). The formally ring-opened 2-acyl-2'-hydroxy biaryls, which interconvert via the lactol isomers 5 as the cyclic (and thus configurationally less stable) intermediates, have a significantly slower atropisomerization rate as a result of the high loss in activation entropy Delta S-double dagger as a consequence of the required intermediate ring closure 4 --> 5.

  DOI：

  10.1021/jo9913356
• 作为产物：
  描述：

  1-(3-氨基-4-甲基苯基)乙酮 在 氢氧化钾 、 一水合肼 作用下， 反应 2.0h， 生成 5-乙基-2-甲基-苯酚
  参考文献：
  名称：

  Buu-Hoi et al., Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1951, vol. 232, p. 1356

  摘要：

  DOI：

文献信息

• 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS
  申请人：Tansna Therapeutics Inc.

  公开号：US20150148430A1

  公开（公告）日：2015-05-28

  The present disclosure provides phenolic compounds useful in the treatment of neurological conditions such as convulsions and tremors, having the structure of Formula (I): wherein R 2 , R 4 , & R 5 , are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating neurological conditions.

  本公开提供用于治疗诸如惊厥和震颤等神经学状况的酚类化合物，其具有公式（I）的结构： 其中R2、R4和R5如详细描述中定义；包含至少一种该化合物的药物组合物；以及用于治疗神经学状况的方法。
• Raf inhibitor compounds and methods of use thereof
  申请人：Miknis Greg

  公开号：US20070049603A1

  公开（公告）日：2007-03-01

  Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  公式I的化合物对抑制Raf激酶和治疗由此介导的疾病有用。公开了使用公式I的化合物及其立体异构体、几何异构体、互变异构体、溶剂合物和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• [EN] NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS IMMUNOMODULATEURS ET ANTI-INFLAMMATOIRES
  申请人：INCOZEN THERAPEUTICS PVT LTD

  公开号：WO2011138665A1

  公开（公告）日：2011-11-10

  The present invention provides dihydroorotate dehydrogenase inhibitors of formula (I), methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.

  本发明提供了式(I)的脱氢二氢乳酸脱氢酶抑制剂，其制备方法，含有它们的药物组合物以及治疗、预防和/或改善已知抑制二氢乳酸脱氢酶显示有益效果的疾病或疾病的方法。
• Compounds that modulate PPAR activity and methods of preparation
  申请人：——

  公开号：US20030207924A1

  公开（公告）日：2003-11-06

  This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses methods for making the disclosed compounds.

  这项发明揭示了能够改变PPAR活性的化合物。该发明还揭示了这些化合物的药用盐、包含这些化合物或其盐的药用组合物，以及将它们用作治疗或预防哺乳动物高脂血症和高胆固醇血症的治疗剂的方法。本发明还揭示了制备所述化合物的方法。
• Kinase antagonists
  申请人：Knight A. Zachary

  公开号：US20070293516A1

  公开（公告）日：2007-12-20

  The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tryosine kinase, PI3Kinase and mTOR, or PI3Kinase, mTOR and tryosine kinase.

  本发明提供了一种新型化合物，它们是 PI3 激酶、PI3 激酶和酪氨酸激酶、PI3 激酶和 mTOR，或者 PI3 激酶、mTOR 和酪氨酸激酶的拮抗剂。